Neuroimaging in the early diagnosis of neurodegenerative disease
暂无分享,去创建一个
[1] Dag Aarsland,et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.
[2] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] J O Rinne,et al. Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.
[4] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[5] C. DeCarli,et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.
[6] John T. O'Brien,et al. Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.
[7] A. Kertesz,et al. Volumetric study of lobar atrophy in Pick complex and Alzheimer’s disease , 2000, Journal of the Neurological Sciences.
[8] M. Yoshita,et al. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy , 1998, Journal of the Neurological Sciences.
[9] Michael J. Adam,et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.
[10] D. Loewenstein,et al. A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer’s Disease , 2009, Behavioural neurology.
[11] N. Quinn,et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An 18F‐dopa PET progression study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[12] R P Maguire,et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. , 1997, Brain : a journal of neurology.
[13] M. Bobinski,et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Killiany,et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.
[15] Aldo Quattrone,et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[16] J. Molinuevo,et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study , 2011, The Lancet Neurology.
[17] G. Frisoni,et al. Functional network disruption in the degenerative dementias , 2011, The Lancet Neurology.
[18] G. Arabia,et al. MRI measurements predict PSP in unclassifiable parkinsonisms , 2011, Neurology.
[19] Anna Barnes,et al. FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.
[20] M. De Hert,et al. Cost of disorders of the brain in Europe. , 2006, European journal of neurology.
[21] Chris C. Tang,et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.
[22] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[23] J. Olesen,et al. Cost of disorders of the brain in Europe , 2005, European journal of neurology.
[24] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[25] A. Stefani,et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.
[26] H. Arai,et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies , 2000, Neurology.
[27] H. Berendse,et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.
[28] N. Cairns,et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.
[29] Johannes T Heverhagen,et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. , 2010, Sleep.
[30] Paola Piccini,et al. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.
[31] Francesco Fera,et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.
[32] S. Gilman,et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] B. Miller,et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.
[34] I. Podreka,et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .
[35] C Büchel,et al. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. , 2005, Brain : a journal of neurology.
[36] J. Langston,et al. Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.
[37] C. Rowe,et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.
[38] Daoqiang Zhang,et al. Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.
[39] R. Chervin,et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder , 2000, Neurology.
[40] Massimo Filippi,et al. A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[41] Pablo Mir,et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[42] C. DeCarli,et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.
[43] M. Viitanen,et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.
[44] T. Krause,et al. Impaired cardiac uptake of meta‐[123 I]iodobenzylguanidine in Parkinson's disease with autonomic failure , 1998, Acta neurologica Scandinavica.
[45] Michael Schocke,et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion‐tensor imaging and voxel‐based morphometry study , 2011, Annals of neurology.
[46] F. Tison,et al. Oral zolmitriptan is effective in the acute treatment of cluster headache , 2000, Neurology.
[47] J. Molinuevo,et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder , 2009, Movement disorders : official journal of the Movement Disorder Society.
[48] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[49] C Kremser,et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.
[50] F Barkhof,et al. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD , 2003, Neurology.
[51] Thomas Hummel,et al. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[52] S. Asenbaum,et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.
[53] Cindee M. Madison,et al. Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.
[54] B. R. Bloem,et al. Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype , 2009, Neurology.
[55] Pablo Mir,et al. Patients with adult‐onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs) , 2007, Movement disorders : official journal of the Movement Disorder Society.
[56] Vesna Sossi,et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.
[57] David Neil Manners,et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.. Dec 15;23(16):2370-6.PMID: 18816803 , 2008 .
[58] M. Albert,et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.
[59] C. Jack,et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.
[60] Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.
[61] J. Os,et al. Cost of disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.
[62] Daniela Berg,et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.
[63] V. Sossi,et al. Progression of dopaminergic dysfunction in a LRRK2 kindred , 2008, Neurology.
[64] V. Sossi,et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers , 2010, Movement disorders : official journal of the Movement Disorder Society.
[65] Efstathios D. Gennatas,et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. , 2010, Brain : a journal of neurology.
[66] K. Arai,et al. Study of the rostral midbrain atrophy in progressive supranuclear palsy , 2003, Journal of the Neurological Sciences.
[67] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[68] Li Shen,et al. Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.
[69] M. Vendette,et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder , 2009, Neurology.
[70] D. Goldstein,et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. , 2008, Parkinsonism & related disorders.
[71] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[72] Nick C Fox,et al. Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.
[73] A. Convit,et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.
[74] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[75] C Büchel,et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia , 2007, Neurology.
[76] Nick C Fox,et al. Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease , 2008, American Journal of Neuroradiology.
[77] A J Lees,et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs) , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.
[78] J. Patterson,et al. Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP‐CIT SPECT , 2006, Movement disorders : official journal of the Movement Disorder Society.
[79] J. Patterson,et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging , 2006, Nuclear medicine communications.
[80] Satoshi Minoshima,et al. Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.
[81] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[82] C. Becker,et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics , 2009, Neurobiology of Disease.
[83] Paola Piccini,et al. Clinical and subclinical dopaminergic dysfunction in PARK6‐linked parkinsonism: An 18F‐dopa PET study , 2002, Annals of neurology.
[84] Vinod Menon,et al. Functional connectivity in the resting brain: A network analysis of the default mode hypothesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.